$319.37
+0.20%Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Strong net margins indicate efficient operations and favorable tax/interest management.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
PEN โข NYSE
| Penumbra, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
1.4B | 1.2B | 1.1B | 847.1M | 747.6M | 560.4M | 547.4M | 444.9M | 333.8M | 263.3M | 186.1M | 125.5M | 88.8M | 73.1M | |
GROSS PROFIT | ||||||||||||||
(461.2M) | (439.6M) | (375.9M) | (311.9M) | (272.2M) | (222.2M) | (175.4M) | (152.4M) | (116.6M) | (92.5M) | (62M) | (42.7M) | (31M) | (24.2M) | |
942.4M | 755M | 682.6M | 535.2M | 475.4M | 338.2M | 372M | 292.5M | 217.1M | 170.8M | 124.1M | 82.8M | 57.9M | 49M | |
OPERATING INCOME | ||||||||||||||
(753.2M) | (745.7M) | (609.1M) | (529.1M) | (482.9M) | (377.1M) | (324.5M) | (293.4M) | (216M) | (172.2M) | (119.9M) | (79.8M) | (59M) | (45.5M) | |
(663.4M) | (574M) | (506.5M) | (449.7M) | (378.3M) | (287.1M) | (272.7M) | (226.4M) | (184.3M) | (148.3M) | (101.9M) | (64.3M) | (44.9M) | (33M) | |
(89.8M) | (94.8M) | (84.4M) | (79.4M) | (104.6M) | (90M) | (51.7M) | (36.2M) | (31.7M) | (23.9M) | (18M) | (15.6M) | (14.1M) | (12.5M) | |
189.2M | 9.3M | 73.6M | 6.1M | -7.5M | -38.9M | 47.5M | -852K | 1.2M | -1.4M | 4.2M | 3M | -1.1M | 3.4M | |
PRE-TAX INCOME | ||||||||||||||
(0.0) | (1.4M) | (1.7M) | (1.7M) | (1.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 12.3M | 5.1M | 137K | 938K | 1.3M | 2.9M | 3M | 2.7M | 2.3M | 541K | 439K | 345K | 244K | |
(0.0) | (76.9M) | (18.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (30.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
15.9M | 11.6M | 6.1M | -2.2M | -3M | 924K | 2.6M | 2.5M | 1.3M | 481K | -155K | 130K | -129K | 464K | |
205.1M | 20.9M | 79.7M | 3.9M | -10.5M | -38M | 50.1M | 1.6M | 2.5M | -869K | 4M | 3.1M | -1.3M | 3.9M | |
NET INCOME | ||||||||||||||
(27.4M) | (6.9M) | -11.3M | (5.9M) | -13.1M | -18.8M | (3.1M) | -4.4M | -3.6M | -15.7M | (1.7M) | (894K) | -5.4M | (1.9M) | |
177.7M | 14M | 91M | -2M | 5.3M | -15.7M | 48.5M | 6.6M | 4.7M | 14.8M | 2.4M | 2.2M | 4.1M | 2M |
PEN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 15, 2026 | January 14, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 27, 2025 | August 22, 2025 | 2025 |
Continue your PEN research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.